var data={"title":"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/contributors\" class=\"contributor contributor_credentials\">Scott A Laurie, MD, FRCPC</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/contributors\" class=\"contributor contributor_credentials\">Bruce E Brockstein, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/contributors\" class=\"contributor contributor_credentials\">David M Brizel, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/contributors\" class=\"contributor contributor_credentials\">Marvin P Fried, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/contributors\" class=\"contributor contributor_credentials\">Michael E Ross, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 30, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>This topic discusses the clinical presentation, diagnosis, initial evaluation, and staging of salivary gland tumors.</p><p>Other important topics related to salivary gland tumors include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=salivary-gland-tumors-treatment-of-locoregional-disease\" class=\"medical medical_review\">&quot;Salivary gland tumors: Treatment of locoregional disease&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=malignant-salivary-gland-tumors-treatment-of-recurrent-and-metastatic-disease\" class=\"medical medical_review\">&quot;Malignant salivary gland tumors: Treatment of recurrent and metastatic disease&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pathology-of-head-and-neck-neoplasms#H84270800\" class=\"medical medical_review\">&quot;Pathology of head and neck neoplasms&quot;, section on 'Salivary gland tumors'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H267160259\"><span class=\"h1\">SPECTRUM OF SALIVARY GLAND TUMORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Salivary gland tumors constitute an uncommon, heterogeneous group of neoplasms that vary considerably in their anatomic site of origin, histology, and biologic behavior (<a href=\"image.htm?imageKey=PC%2F115303\" class=\"graphic graphic_figure graphicRef115303 \">figure 1</a>). Both benign and malignant salivary gland tumors are classified according to the 2005 World Health Organization (WHO) system (<a href=\"image.htm?imageKey=ONC%2F70453\" class=\"graphic graphic_table graphicRef70453 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=pathology-of-head-and-neck-neoplasms#H84270800\" class=\"medical medical_review\">&quot;Pathology of head and neck neoplasms&quot;, section on 'Salivary gland tumors'</a>.)</p><p>Anatomically, the parotid gland is the most frequent site of salivary gland tumors, accounting for approximately 80 to 85 percent of these tumors [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Approximately three-fourths of parotid lesions are benign, and approximately 25 percent are malignant [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Less frequently, salivary gland tumors originate in the submandibular, sublingual, and minor salivary glands, which are located throughout the submucosa of the mouth and upper aerodigestive tract [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/2\" class=\"abstract_t\">2</a>]. In contrast to tumors arising in the parotid, 40 to 45 percent of submandibular gland tumors, 70 to 90 percent of sublingual gland tumors, and 50 to 75 percent of minor salivary gland tumors are malignant.</p><p>Histologically, the most common type of benign salivary gland tumor is pleomorphic adenoma, which comprises approximately half of all salivary tumors. Other rarer benign salivary gland tumors include Warthin tumor, basal cell adenoma, and canalicular adenoma. (See <a href=\"topic.htm?path=pathology-of-head-and-neck-neoplasms#H84270800\" class=\"medical medical_review\">&quot;Pathology of head and neck neoplasms&quot;, section on 'Salivary gland tumors'</a>.)</p><p>The most common malignant salivary gland tumors are mucoepidermoid carcinoma and adenoid cystic carcinoma, which together comprise approximately one-half of all malignant salivary gland tumors [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p>Salivary gland cancers vary in their aggressiveness and their propensity to recur and metastasize. A histologic grading system has been proposed in which salivary gland malignancies are classified as high grade or low to intermediate grade based upon clinical behavior and outcomes (<a href=\"image.htm?imageKey=ONC%2F64529\" class=\"graphic graphic_table graphicRef64529 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/1,2\" class=\"abstract_t\">1,2</a>]. A higher tumor grade appears to correlate with more aggressive behavior in mucoepidermoid carcinoma and adenocarcinoma not otherwise specified, but there are conflicting data on the importance of grading according to histological pattern in adenoid cystic carcinoma. (See <a href=\"topic.htm?path=pathology-of-head-and-neck-neoplasms#H84270800\" class=\"medical medical_review\">&quot;Pathology of head and neck neoplasms&quot;, section on 'Salivary gland tumors'</a>.) </p><p>Other rare but aggressive salivary gland tumors include primary small cell carcinomas, which account for approximately 1 to 2 percent of all salivary gland tumors and often have distant disease at presentation, and salivary ductal carcinoma, a cancer of older men [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/6\" class=\"abstract_t\">6</a>]. (See <a href=\"topic.htm?path=extrapulmonary-small-cell-cancer#H18\" class=\"medical medical_review\">&quot;Extrapulmonary small cell cancer&quot;, section on 'Salivary gland ESCC'</a>.)</p><p>In addition to primary tumors arising the salivary glands, other malignancies that arise in the head and neck region (eg, lymphoma, cutaneous squamous cell carcinoma, melanoma) can present as major salivary gland masses due to lymph node metastases [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/1,7\" class=\"abstract_t\">1,7</a>]. These may account for up to 10 percent of major salivary gland masses. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-cutaneous-squamous-cell-carcinoma-scc\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)&quot;</a> and <a href=\"topic.htm?path=classification-of-the-hematopoietic-neoplasms#H8\" class=\"medical medical_review\">&quot;Classification of the hematopoietic neoplasms&quot;, section on 'Lymphoid neoplasms'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY AND RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Salivary gland tumors are rare, representing only 6 to 8 percent of head and neck tumors; in the United States, there are approximately 2000 to 2500 cases per year [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/1,2\" class=\"abstract_t\">1,2</a>]. There are substantial geographic variations in the incidence of salivary gland tumors and in the types of tumors in a given area.</p><p>Although there is no one predominant factor known to be associated with the development of salivary gland cancer, a number of factors have been implicated as potential causes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Radiation exposure has been associated with the development of both benign and malignant salivary gland tumors. This relationship was initially based upon data from atomic bomb survivors in Japan [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/8\" class=\"abstract_t\">8</a>]. There also appears to be an increased risk in long-term cancer survivors who received radiation therapy as part of their treatment for Hodgkin lymphoma [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/9,10\" class=\"abstract_t\">9,10</a>] and in individuals who received radiation to the head and neck region for childhood cancers or benign conditions [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/11,12\" class=\"abstract_t\">11,12</a>]. Those with a prior history of Hodgkin lymphoma may be at risk of onset of a salivary cancer at a younger-than-typical age for this malignancy [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/10\" class=\"abstract_t\">10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Warthin tumor has a strong association with smoking, in contrast to other salivary gland tumors for which there is no clear relationship. Although this benign tumor has been historically associated with older men, the incidence in women has increased and parallels the increased smoking rates of women [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/1,13,14\" class=\"abstract_t\">1,13,14</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Viral infections may be associated with an increased risk of salivary gland cancers.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Epstein Barr virus (EBV)</strong> &ndash; Lymphoepithelial carcinoma is an undifferentiated carcinoma that accounts for less than 1 percent of salivary gland tumors; lymphoepithelial carcinoma has been strongly associated with EBV in areas where EBV is endemic [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Human immunodeficiency virus (HIV)</strong> &ndash; Epidemiologic studies have reported an increased incidence of these tumors in individuals infected with HIV [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/15,16\" class=\"abstract_t\">15,16</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Human papillomavirus (HPV)</strong> &ndash; While high-risk serotypes [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/17,18\" class=\"abstract_t\">17,18</a>] of HPV have occasionally been detected in mucoepidermoid carcinoma [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/19,20\" class=\"abstract_t\">19,20</a>], others have not confirmed this observation [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/21\" class=\"abstract_t\">21</a>], and it has only rarely been detected in other salivary cancers [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/22-24\" class=\"abstract_t\">22-24</a>]. There are no conclusive data that support a causative role for HPV in the etiology of salivary gland cancers.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Environmental factors and industrial exposure to factors such as rubber manufacturing, hair dressers, beauty shops, and nickel compounds have been reported to be associated with the development of salivary gland tumors [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/2,25,26\" class=\"abstract_t\">2,25,26</a>].</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical presentation of a salivary gland neoplasm depends upon its specific site of origin and the extent of involvement of adjacent organs.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with a tumor of a major salivary gland typically present with a painless mass or swelling of the parotid, submandibular, or sublingual gland. The presence of a parotid mass in combination with signs or symptoms indicative of facial nerve involvement (eg, facial nerve paralysis) is generally indicative of a malignant rather than a benign tumor.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Minor salivary gland tumors arising within the oral cavity may present with a painless submucosal mass or mucosal ulceration in the palate, lips, or buccal mucosa, with an appearance similar to sialometaplasia (squamous metaplasia of salivary glands) or squamous cell carcinoma. Symptoms due to more advanced minor salivary gland tumors are a function of the location of the tumor and can include nasal obstruction, congestion, vision changes, or trismus when present in the nasal cavity or maxillary sinus. Minor salivary gland tumors involving the nasopharynx usually present at an advanced stage; invasion of the skull base, intracranial extension, or involvement of cranial nerves is common [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/27\" class=\"abstract_t\">27</a>].</p><p/><p>Tumors with a high malignant potential are more likely to spread to regional lymph nodes and result in a palpable mass (<a href=\"image.htm?imageKey=ONC%2F64529\" class=\"graphic graphic_table graphicRef64529 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/4\" class=\"abstract_t\">4</a>]. Lymphatic drainage varies according to the location of the salivary gland. For parotid malignancies, which constitute the majority of salivary gland tumors, the first site of lymphatic spread is the intraparotid lymph nodes, followed by level I and level II cervical nodes (<a href=\"image.htm?imageKey=ONC%2F69528\" class=\"graphic graphic_figure graphicRef69528 \">figure 2</a>). Submandibular gland tumors spread to adjacent perivascular nodes and then to the cervical region. The sublingual gland drains to the submental and submandibular nodes, and the minor salivary glands within the oropharynx drain to the retropharyngeal nodes. (See <a href=\"topic.htm?path=evaluation-of-a-neck-mass-in-adults#H7\" class=\"medical medical_review\">&quot;Evaluation of a neck mass in adults&quot;, section on 'Physical examination'</a>.) </p><p>Distant metastases most frequently localize to lung, followed by bone and liver [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/17\" class=\"abstract_t\">17</a>]. Adenoid cystic carcinoma is associated with a high risk of distant metastases, which can occur as late as 10 to 20 years after diagnosis and treatment [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H6966761\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A wide range of pathologic processes can cause a salivary gland mass or enlargement. In addition to benign and malignant tumors, the differential diagnosis of patients includes salivary cysts, cysts of the first branchial cleft, salivary gland stones, sarcoid, Sj&ouml;gren syndrome, metastases from other tumors, lymphoepithelial cysts (particularly in an immunocompromised host), chronic sclerosing sialadenitis (K&uuml;ttner tumor), and regional lymphadenopathy from infectious, inflammatory, or malignant diseases. Distinguishing among these possibilities may require a tissue diagnosis. (See <a href=\"topic.htm?path=differential-diagnosis-of-a-neck-mass\" class=\"medical medical_review\">&quot;Differential diagnosis of a neck mass&quot;</a>.)</p><p>In patients presenting with facial nerve palsy, a high suspicion of malignant involvement of the parotid gland must be entertained in those with a history of skin cancer or melanoma of the scalp or face, as well as in those with a history of removal of a skin lesion that was not sent for pathologic examination.</p><p>A malignant parotid tumor must be distinguished from Bell palsy. Patients with apparent Bell palsy require further evaluation if there are other neurologic abnormalities, there are features on physical examination that suggest a parotid tumor, or there is no evidence of improvement within a reasonable time frame [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=bells-palsy-pathogenesis-clinical-features-and-diagnosis-in-adults#H10\" class=\"medical medical_review\">&quot;Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults&quot;, section on 'Imaging studies'</a>.)</p><p>Other rare causes of facial nerve paralysis that must be distinguished from a parotid tumor include sarcoid infiltration of the parotid gland (known as Heerfordt syndrome) and intraparotid facial nerve schwannoma [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/18\" class=\"abstract_t\">18</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of pulmonary sarcoidosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H267160930\"><span class=\"h1\">INITIAL ASSESSMENT</span></p><p class=\"headingAnchor\" id=\"H598833401\"><span class=\"h2\">History and physical examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The initial history should evaluate the duration the mass has been present, the rapidity of its growth, and the presence of pain, numbness, or any subtle asymmetry of facial motion. In addition, the patient should be questioned for a history of previous skin cancers, such as squamous cell carcinoma or melanoma of the scalp or facial region. (See <a href=\"topic.htm?path=evaluation-of-a-neck-mass-in-adults\" class=\"medical medical_review\">&quot;Evaluation of a neck mass in adults&quot;</a>.)</p><p>Physical examination should document the size of the mass, its mobility, fixation to overlying skin or to deep structures, any limitation in jaw opening, pharyngeal asymmetry or buccal involvement, pain with palpation, skin or scalp lesions suggestive of primary malignancy, and a detailed facial nerve examination that details specific branch involvement if present. Examination of the neck should include assessment for cervical lymphadenopathy.</p><p class=\"headingAnchor\" id=\"H598833408\"><span class=\"h2\">Imaging studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The role of imaging studies in addition to physical examination in the evaluation of salivary gland tumors is to differentiate neoplastic from benign disease, define intra- versus extraglandular location, assess local extension and invasion, and detect nodal and systemic metastases.</p><p>The initial imaging evaluation varies in part based upon the location of the enlarged gland:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Both computed tomography (CT) and magnetic resonance imaging (MRI) may be necessary to assess the extent of a salivary gland tumor, which may be greater than can be appreciated on physical examination. Such imaging is also useful to evaluate local, bony, and perineural invasion and lymph node metastases, as well as to assess the parapharyngeal space for involvement from lesions in the parotid [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/29,30\" class=\"abstract_t\">29,30</a>]. MRI is suggested in the evaluation of all sublingual gland tumors given the high risk for malignant disease. Temporal bone or mandibular destruction is best identified by CT, while MRI permits more detailed evaluation of soft tissue infiltration, perineural invasion, and intracranial extension [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/31\" class=\"abstract_t\">31</a>]. In addition, CT or MRI can provide anatomic details that are useful for surgical planning.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Depending upon the location and size of a mass, ultrasound may also provide high-quality resolution and tissue characterization while being timely and cost effective for imaging the parotid, submandibular, and sublingual glands [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/32,33\" class=\"abstract_t\">32,33</a>]. These glands are superficial structures and are readily amenable to high-resolution ultrasound examination. In addition, ultrasound can facilitate fine needle aspiration (FNA) and core needle biopsy [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/34,35\" class=\"abstract_t\">34,35</a>]. Ultrasound is not as useful as other modalities for planning surgical treatment.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When a Warthin tumor is diagnosed, both parotid glands should be imaged since these tumors have a tendency for multifocality and bilaterality [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/36,37\" class=\"abstract_t\">36,37</a>]. Synchronous bilateral malignancy in the parotid glands is rare in other histologic tumor types [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/38\" class=\"abstract_t\">38</a>].</p><p/><p class=\"headingAnchor\" id=\"H6966596\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A tissue diagnosis is required to make the diagnosis of a salivary gland tumor and to determine whether such a tumor is benign or malignant.</p><p>The tissue diagnosis should be obtained prior to definitive treatment whenever possible to avoid major surgery for a benign tumor or a lymphoma [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/2\" class=\"abstract_t\">2</a>]. Options include fine needle aspiration (FNA) or ultrasound-guided core needle biopsy [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/39-41\" class=\"abstract_t\">39-41</a>]. Both techniques are safe, simple procedures that can help direct subsequent evaluation <span class=\"nowrap\">and/or</span> treatment. (See <a href=\"topic.htm?path=salivary-gland-tumors-treatment-of-locoregional-disease\" class=\"medical medical_review\">&quot;Salivary gland tumors: Treatment of locoregional disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">STAGING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cancers of the major glands are staged according to the eighth edition (2017) of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) tumor, node, metastasis (TNM) system (<a href=\"image.htm?imageKey=ONC%2F110617\" class=\"graphic graphic_table graphicRef110617 \">table 3</a> and <a href=\"image.htm?imageKey=ONC%2F110657\" class=\"graphic graphic_table graphicRef110657 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/42\" class=\"abstract_t\">42</a>]. Tumors arising in minor salivary glands are staged similar to squamous cell carcinoma, according to their anatomic site of origin.</p><p>Imaging studies (computed tomography [CT], magnetic resonance imaging [MRI]) that are obtained prior to diagnosis can provide important information for staging in those patients who are ultimately found to have a malignant tumor. Although not routine in the evaluation of all malignant salivary gland tumors, fludeoxyglucose (FDG) positron emission tomography (PET) has good diagnostic accuracy in the assessment of regional lymph nodes and distant metastases in patients with salivary gland malignancies [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/43-45\" class=\"abstract_t\">43-45</a>]. Integrated <span class=\"nowrap\">PET/CT</span> may be more accurate than PET alone [<a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/46\" class=\"abstract_t\">46</a>]. However, PET is not able to distinguish benign from malignant parotid tumors. CT may also be useful to examine the chest to rule out lung metastases.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Salivary gland tumors comprise a rare, diverse group of benign and malignant histologies. Most salivary gland tumors are benign and occur in the parotid gland. Pleomorphic adenoma is the most common of these benign lesions. Tumors of the submandibular, sublingual, and minor salivary glands are more likely than parotid tumors to be malignant. (See <a href=\"#H267160259\" class=\"local\">'Spectrum of salivary gland tumors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients with salivary gland tumors present with a painless mass or swelling. However, the differential diagnosis of a salivary gland mass includes a wide range of cystic and inflammatory disorders as well as benign and malignant tumors (<a href=\"image.htm?imageKey=ONC%2F70453\" class=\"graphic graphic_table graphicRef70453 \">table 1</a>). Neurologic signs or symptoms, such as facial nerve paralysis, indicative of facial nerve involvement, are almost always indicative of a malignant tumor. (See <a href=\"#H4\" class=\"local\">'Clinical presentation'</a> above and <a href=\"#H6966761\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A tissue diagnosis is required to establish a definitive diagnosis of a salivary gland tumor and to plan therapy. If anatomically feasible, a preoperative biopsy (either fine needle aspiration [FNA] cytology or ultrasound-guided core needle) can be performed to avoid operating on a nonsurgically managed disease process and to aid in surgical planning. However, a preoperative histologic diagnosis is not always possible. (See <a href=\"#H267160930\" class=\"local\">'Initial assessment'</a> above and <a href=\"#H6966596\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malignancies of the parotid, submandibular, and sublingual glands are staged according to the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) tumor, node, metastasis (TNM) system (<a href=\"image.htm?imageKey=ONC%2F110617\" class=\"graphic graphic_table graphicRef110617 \">table 3</a> and <a href=\"image.htm?imageKey=ONC%2F110657\" class=\"graphic graphic_table graphicRef110657 \">table 4</a>). Tumors arising in minor salivary glands are staged according to their anatomic site of origin. Imaging studies using computed tomography (CT), magnetic resonance imaging (MRI), and in some cases positron emission tomography (PET) may provide important information about the extent of local invasion or dissemination. (See <a href=\"#H7\" class=\"local\">'Staging'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Tumours of the Salivary Glands. In: Pathology and Genetics of Head and Neck Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D (Eds), World Health Organization, Lyon 2005. p.209.</li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/2\" class=\"nounderline abstract_t\">Guzzo M, Locati LD, Prott FJ, et al. Major and minor salivary gland tumors. Crit Rev Oncol Hematol 2010; 74:134.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/3\" class=\"nounderline abstract_t\">Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986; 8:177.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/4\" class=\"nounderline abstract_t\">Xiao CC, Zhan KY, White-Gilbertson SJ, Day TA. Predictors of Nodal Metastasis in Parotid Malignancies: A National Cancer Data Base Study of 22,653 Patients. Otolaryngol Head Neck Surg 2016; 154:121.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/5\" class=\"nounderline abstract_t\">Dillon PM, Chakraborty S, Moskaluk CA, et al. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head Neck 2016; 38:620.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/6\" class=\"nounderline abstract_t\">Jayaprakash V, Merzianu M, Warren GW, et al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck 2014; 36:694.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/7\" class=\"nounderline abstract_t\">O'Brien CJ, Malka VB, Mijailovic M. Evaluation of 242 consecutive parotidectomies performed for benign and malignant disease. Aust N Z J Surg 1993; 63:870.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/8\" class=\"nounderline abstract_t\">Saku T, Hayashi Y, Takahara O, et al. Salivary gland tumors among atomic bomb survivors, 1950-1987. Cancer 1997; 79:1465.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/9\" class=\"nounderline abstract_t\">Boukheris H, Ron E, Dores GM, et al. Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. Cancer 2008; 113:3153.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/10\" class=\"nounderline abstract_t\">Chowdhry AK, McHugh C, Fung C, et al. Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma. Cancer 2015; 121:1436.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/11\" class=\"nounderline abstract_t\">Schneider AB, Lubin J, Ron E, et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. Radiat Res 1998; 149:625.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/12\" class=\"nounderline abstract_t\">Boukheris H, Stovall M, Gilbert ES, et al. Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys 2013; 85:776.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/13\" class=\"nounderline abstract_t\">Pinkston JA, Cole P. Cigarette smoking and Warthin's tumor. Am J Epidemiol 1996; 144:183.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/14\" class=\"nounderline abstract_t\">de Ru JA, Plantinga RF, Majoor MH, et al. Warthin's tumour and smoking. B-ENT 2005; 1:63.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/15\" class=\"nounderline abstract_t\">Serraino D, Boschini A, Carrieri P, et al. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS 2000; 14:553.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/16\" class=\"nounderline abstract_t\">Shebl FM, Bhatia K, Engels EA. Salivary gland and nasopharyngeal cancers in individuals with acquired immunodeficiency syndrome in United States. Int J Cancer 2010; 126:2503.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/17\" class=\"nounderline abstract_t\">Licitra L, Grandi C, Prott FJ, et al. Major and minor salivary glands tumours. Crit Rev Oncol Hematol 2003; 45:215.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/18\" class=\"nounderline abstract_t\">Caughey RJ, May M, Schaitkin BM. Intraparotid facial nerve schwannoma: diagnosis and management. Otolaryngol Head Neck Surg 2004; 130:586.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/19\" class=\"nounderline abstract_t\">Isayeva T, Said-Al-Naief N, Ren Z, et al. Salivary mucoepidermoid carcinoma: demonstration of transcriptionally active human papillomavirus 16/18. Head Neck Pathol 2013; 7:135.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/20\" class=\"nounderline abstract_t\">Brunner M, Koperek O, Wrba F, et al. HPV infection and p16 expression in carcinomas of the minor salivary glands. Eur Arch Otorhinolaryngol 2012; 269:2265.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/21\" class=\"nounderline abstract_t\">Jour G, West K, Ghali V, et al. Differential expression of p16(INK4A) and cyclin D1 in benign and malignant salivary gland tumors: a study of 44 Cases. Head Neck Pathol 2013; 7:224.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/22\" class=\"nounderline abstract_t\">Hafed L, Farag H, Shaker O, El-Rouby D. Is human papilloma virus associated with salivary gland neoplasms? An in situ-hybridization study. Arch Oral Biol 2012; 57:1194.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/23\" class=\"nounderline abstract_t\">Sk&aacute;lov&aacute; A, Ka&scaron;p&iacute;rkov&aacute; J, Andrle P, et al. Human papillomaviruses are not involved in the etiopathogenesis of salivary gland tumors. Cesk Patol 2013; 49:72.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/24\" class=\"nounderline abstract_t\">Boland JM, McPhail ED, Garc&iacute;a JJ, et al. Detection of human papilloma virus and p16 expression in high-grade adenoid cystic carcinoma of the head and neck. Mod Pathol 2012; 25:529.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/25\" class=\"nounderline abstract_t\">Horn-Ross PL, Ljung BM, Morrow M. Environmental factors and the risk of salivary gland cancer. Epidemiology 1997; 8:414.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/26\" class=\"nounderline abstract_t\">Swanson GM, Burns PB. Cancers of the salivary gland: workplace risks among women and men. Ann Epidemiol 1997; 7:369.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/27\" class=\"nounderline abstract_t\">Schramm VL Jr, Imola MJ. Management of nasopharyngeal salivary gland malignancy. Laryngoscope 2001; 111:1533.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/28\" class=\"nounderline abstract_t\">Quesnel AM, Lindsay RW, Hadlock TA. When the bell tolls on Bell's palsy: finding occult malignancy in acute-onset facial paralysis. Am J Otolaryngol 2010; 31:339.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/29\" class=\"nounderline abstract_t\">Lee YY, Wong KT, King AD, Ahuja AT. Imaging of salivary gland tumours. Eur J Radiol 2008; 66:419.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/30\" class=\"nounderline abstract_t\">Hisatomi M, Asaumi J, Yanagi Y, et al. Diagnostic value of dynamic contrast-enhanced MRI in the salivary gland tumors. Oral Oncol 2007; 43:940.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/31\" class=\"nounderline abstract_t\">Koyuncu M, Se&#351;en T, Akan H, et al. Comparison of computed tomography and magnetic resonance imaging in the diagnosis of parotid tumors. Otolaryngol Head Neck Surg 2003; 129:726.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/32\" class=\"nounderline abstract_t\">Kotecha S, Bhatia P, Rout PG. Diagnostic ultrasound in the head and neck region. Dent Update 2008; 35:529.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/33\" class=\"nounderline abstract_t\">Koischwitz D, Gritzmann N. Ultrasound of the neck. Radiol Clin North Am 2000; 38:1029.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/34\" class=\"nounderline abstract_t\">Bia&#322;ek EJ, Jakubowski W, Karpi&#324;ska G. Role of ultrasonography in diagnosis and differentiation of pleomorphic adenomas: work in progress. Arch Otolaryngol Head Neck Surg 2003; 129:929.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/35\" class=\"nounderline abstract_t\">Feld R, Nazarian LN, Needleman L, et al. Clinical impact of sonographically guided biopsy of salivary gland masses and surrounding lymph nodes. Ear Nose Throat J 1999; 78:905, 908.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/36\" class=\"nounderline abstract_t\">Maiorano E, Lo Muzio L, Favia G, Piattelli A. Warthin's tumour: a study of 78 cases with emphasis on bilaterality, multifocality and association with other malignancies. Oral Oncol 2002; 38:35.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/37\" class=\"nounderline abstract_t\">Hilton JM, Phillips JS, Hellquist HB, Premachandra DJ. Multifocal multi-site Warthin tumour. Eur Arch Otorhinolaryngol 2008; 265:1573.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/38\" class=\"nounderline abstract_t\">van Tongeren J, Creytens DH, Meulemans EV, et al. Synchronous bilateral epithelial-myoepithelial carcinoma of the parotid gland: case report and review of the literature. Eur Arch Otorhinolaryngol 2009; 266:1495.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/39\" class=\"nounderline abstract_t\">Christensen RK, Bj&oslash;rndal K, Godballe C, Krogdahl A. Value of fine-needle aspiration biopsy of salivary gland lesions. Head Neck 2010; 32:104.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/40\" class=\"nounderline abstract_t\">Howlett DC, Menezes LJ, Lewis K, et al. Sonographically guided core biopsy of a parotid mass. AJR Am J Roentgenol 2007; 188:223.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/41\" class=\"nounderline abstract_t\">Liu CC, Jethwa AR, Khariwala SS, et al. Sensitivity, Specificity, and Posttest Probability of Parotid Fine-Needle Aspiration: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg 2016; 154:9.</a></li><li class=\"breakAll\">Lydiatt WM, Mukherji SK, O'Sullivan B, et al. Major Salivary Glands. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), Springer, New York 2017. p.95.</li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/43\" class=\"nounderline abstract_t\">Cermik TF, Mavi A, Acikgoz G, et al. FDG PET in detecting primary and recurrent malignant salivary gland tumors. Clin Nucl Med 2007; 32:286.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/44\" class=\"nounderline abstract_t\">Razfar A, Heron DE, Branstetter BF 4th, et al. Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope 2010; 120:734.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/45\" class=\"nounderline abstract_t\">Kim MJ, Kim JS, Roh JL, et al. Utility of 18F-FDG PET/CT for detecting neck metastasis in patients with salivary gland carcinomas: preoperative planning for necessity and extent of neck dissection. Ann Surg Oncol 2013; 20:899.</a></li><li><a href=\"https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging/abstract/46\" class=\"nounderline abstract_t\">Adelstein DJ, Rodriguez CP. What is new in the management of salivary gland cancers? Curr Opin Oncol 2011; 23:249.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3400 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H8\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H267160259\" id=\"outline-link-H267160259\">SPECTRUM OF SALIVARY GLAND TUMORS</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY AND RISK FACTORS</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL PRESENTATION</a></li><li><a href=\"#H6966761\" id=\"outline-link-H6966761\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H267160930\" id=\"outline-link-H267160930\">INITIAL ASSESSMENT</a><ul><li><a href=\"#H598833401\" id=\"outline-link-H598833401\">History and physical examination</a></li><li><a href=\"#H598833408\" id=\"outline-link-H598833408\">Imaging studies</a></li></ul></li><li><a href=\"#H6966596\" id=\"outline-link-H6966596\">DIAGNOSIS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">STAGING</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/3400|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PC/115303\" class=\"graphic graphic_figure\">- Anatomy of the salivary glands and ducts</a></li><li><a href=\"image.htm?imageKey=ONC/69528\" class=\"graphic graphic_figure\">- Lymph nodes head and neck</a></li></ul></li><li><div id=\"ONC/3400|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/70453\" class=\"graphic graphic_table\">- WHO class salivary gld tum</a></li><li><a href=\"image.htm?imageKey=ONC/64529\" class=\"graphic graphic_table\">- Grades salivary gland cancer</a></li><li><a href=\"image.htm?imageKey=ONC/110617\" class=\"graphic graphic_table\">- Major salivary gland tumors TNM 2017 pathologic staging</a></li><li><a href=\"image.htm?imageKey=ONC/110657\" class=\"graphic graphic_table\">- Major salivary gland tumors TNM 2017 clinical staging</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=bells-palsy-pathogenesis-clinical-features-and-diagnosis-in-adults\" class=\"medical medical_review\">Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-of-the-hematopoietic-neoplasms\" class=\"medical medical_review\">Classification of the hematopoietic neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-cutaneous-squamous-cell-carcinoma-scc\" class=\"medical medical_review\">Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of pulmonary sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=differential-diagnosis-of-a-neck-mass\" class=\"medical medical_review\">Differential diagnosis of a neck mass</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-a-neck-mass-in-adults\" class=\"medical medical_review\">Evaluation of a neck mass in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extrapulmonary-small-cell-cancer\" class=\"medical medical_review\">Extrapulmonary small cell cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=malignant-salivary-gland-tumors-treatment-of-recurrent-and-metastatic-disease\" class=\"medical medical_review\">Malignant salivary gland tumors: Treatment of recurrent and metastatic disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathology-of-head-and-neck-neoplasms\" class=\"medical medical_review\">Pathology of head and neck neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=salivary-gland-tumors-treatment-of-locoregional-disease\" class=\"medical medical_review\">Salivary gland tumors: Treatment of locoregional disease</a></li></ul></div></div>","javascript":null}